Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Titration Open-Label Study of Nevanimibe for Classic Congenital Adrenal Hyperplasia
2017-004878-34Phase 2Terminated
- Sponsor
- Millendo Therapeutics
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Nevanimibe in congenital adrenal hyperplasia (CAH), sponsored by Millendo Therapeutics. Primary endpoint: Overall response rate (serum 17-OHP targets). Started Apr 2018; status: terminated.
02
Drugs
Nevanimibe
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on 2017-004878-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004878-34.